Clinical Trials Directory

Trials / Conditions / Ascites Hepatic

Ascites Hepatic

31 registered clinical trials studyying Ascites Hepatic9 currently recruiting.

StatusTrialSponsorPhase
RecruitingEarly TIPS in Patients With Liver Cirrhosis and Ascites
NCT06576934
University Hospital FreiburgN/A
RecruitingAlbumin Assisted Diuresis in Patients with Cirrhosis and Ascites
NCT06812390
Anahita Rabiee MD MHSPhase 2
RecruitingEffectiveness and Safety of TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hyperte
NCT06669806
C. R. BardN/A
RecruitingUnderdilated-stent Technique Improves Post-TIPS Encephalopathy
NCT07349654
The Second Affiliated Hospital of Chongqing Medical UniversityN/A
RecruitingPredictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure
NCT06224023
Carol Davila University of Medicine and Pharmacy
Active Not RecruitingEndothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
NCT06256432
Noorik Biopharmaceuticals AGPhase 2
CompletedA Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administrati
NCT05928624
University of California, San FranciscoN/A
RecruitingSGLT-2 Inhibitors in the Treatment of Ascites
NCT05999773
University of Palermo
TerminatedAchieving Portal Access With Scorpion Post-Approval Study (APASS)
NCT05765253
Argon Medical DevicesN/A
CompletedA Study to Determine Pharmacokinetic Changes of Ceftriaxone in Patients With Liver Cirrhosis
NCT05960006
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
RecruitingQOL and Sarcopenia in Patients With Ascites
NCT05726747
Abramson Cancer Center at Penn Medicine
RecruitingHRS-AKI Treatment With TIPS in Patients With Cirrhosis
NCT05346393
Jena University HospitalN/A
CompletedEmpagliflozin as a Novel Therapy in Refractory Ascites
NCT05430243
Alexandria UniversityPhase 2 / Phase 3
CompletedAchieving Portal Access With Scorpion Post-Approval Study 2
NCT06856655
Argon Medical Devices
UnknownComparison Between Conventional Angiocatheter Versus New Anchoring Device (KARAHOC) Used for Paracentesis
NCT05578573
Sang Gyune KimN/A
RecruitingSingle and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
NCT05490888
PharmaINPhase 1
CompletedEmpagliflozin in Diuretic Refractory Ascites
NCT05013502
Stanford UniversityPhase 1
UnknownS100A8/A9 and Innate Immunity in Liver Disease
NCT05793983
St George's, University of London
UnknownSodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
NCT05014594
Post Graduate Institute of Medical Education and Research, ChandigarhPhase 2
TerminatedRefractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ula
NCT04311489
University of AarhusPhase 2
WithdrawnFresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis
NCT04109144
Montefiore Medical CenterPhase 2
UnknownThe Effect of Terlipressin on Recovery of Liver Function After Hepatectomy
NCT04221672
Shanghai Zhongshan HospitalPhase 3
CompletedA Study of OsrHSA in Adult Healthy Male and Female Volunteers
NCT04384523
Healthgen Biotechnology Corp.Phase 1
UnknownContinuous Passive Paracentesis for Intra-abdominal Hypertension
NCT04322201
Centro Hospitalar de Lisboa CentralN/A
CompletedOutcome After TIPS
NCT03459378
Medical University of Graz
WithdrawnFresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis
NCT03202524
Montefiore Medical CenterPhase 4
CompletedContinuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
NCT03107091
BioVie Inc.Phase 2
TerminatedPEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis
NCT03027635
Nina KimerN/A
CompletedProspective Evaluation of PleurX Drain for Treatment of Cirrhotic Refractory Ascites
NCT04569565
University of AlbertaN/A
CompletedEvaluation of 'Melody' Paracentesis Device for Ascites Therapy
NCT03191851
University of NottinghamN/A
No Longer AvailableReplicor Compassionate Access Program
NCT05683548
Replicor Inc.